Search

Your search keyword '"Sharma, Raman"' showing total 60 results

Search Constraints

Start Over You searched for: Author "Sharma, Raman" Remove constraint Author: "Sharma, Raman" Publication Type Magazines Remove constraint Publication Type: Magazines
60 results on '"Sharma, Raman"'

Search Results

1. Perception of college-going girls towards corneal donation in North India: A latent class analysis study

3. The Drug-Drug Interaction between Erlotinib and OSI-930 Is Mediated through Aldehyde Oxidase Inhibition

4. The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite

5. Mitigating a Bioactivation Liability with an Azetidine-Based Inhibitor of Diacylglycerol Acyltransferase 2 (DGAT2) En Route to the Discovery of the Clinical Candidate Ervogastat

6. Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis

7. A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a 14C‐Microtracer Approach

9. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans

11. Ebola virus antibody decay–stimulation in a high proportion of survivors

12. PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease

13. Management of hunger strike: A medical, ethical and legal conundrum

14. Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases

15. Nonclassical Phenyl Bioisosteres as Effective Replacements in a Series of Novel Open-Source Antimalarials

16. Effective Application of Metabolite Profiling in Drug Design and Discovery

17. Response to a Fire Incident in the Operation Room: A Cautionary Tale

19. In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes

20. Paediatric nasal dermoids: Our experience

21. A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19

22. IVUS Improves Outcomes With SUPERA Stents for the Treatment of Superficial Femoral-Popliteal Artery Disease

23. An unusual indication of maxillectomy—a case presentation of sphenoid wing meningioma

24. MRSA Causing Necrotizing Fasciitis in 18-Month-Old Boy

25. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)

26. Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides

28. Malignant ossifying fibromyxoid tumor of the parapharyngeal space

29. Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes

30. Mesoscopic quantum superposition of the generalized cat state: A diffraction limit.

32. An Engrossing History of Azidothymidine

33. Comparison of the Circulating Metabolite Profile of PF-04991532, a Hepatoselective Glucokinase Activator, Across Preclinical Species and Humans: Potential Implications in Metabolites in Safety Testing Assessment

35. Metabolites in Safety Testing Assessment in Early Clinical Development: A Case Study with a Glucokinase Activator

36. Characterization of T-5 N-Oxide Formation as the First Highly Selective Measure of CYP3A5 Activity

37. Demonstration of the Innate Electrophilicity of 4-(3-(Benzyloxy)phenyl)-2-(ethylsulfinyl)-6-(trifluoromethyl)pyrimidine (BETP), a Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor

38. Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects

39. In Vitro Metabolism of the Glucagon-Like Peptide-1 (GLP-1)–Derived Metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in Mouse and Human Hepatocytes

40. Metabolism, Excretion, and Pharmacokinetics of ((3,3-Difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a Dipeptidyl Peptidase Inhibitor, in Rat, Dog and Human

41. Guidance and Technology: An Assessment of Project Intervention and Promoted Technologies.

42. Immune-Mediated Agranulocytosis Caused by the Cocaine Adulterant Levamisole: A Case for Reactive Metabolite(s) Involvement

43. Deuterium Isotope Effects on Drug Pharmacokinetics. I. System-Dependent Effects of Specific Deuteration with Aldehyde Oxidase Cleared Drugs

44. Investigative Study of Optical Parameters of Se80.5Bi1.5Te18-yAgy Thin Films

45. Validation of Isolated Metabolites from Drug Metabolism Studies as Analytical Standards by Quantitative NMR

48. Age correlation in upper brachial plexus injury patients undergoing nerve transfer surgeries

49. In Vitro Screening Techniques for Reactive Metabolites for Minimizing Bioactivation Potential in Drug Discovery

50. Model for Self-Diffusion Coefficient

Catalog

Books, media, physical & digital resources